Introducing NASOLUTION
The Future of Intranasal Medication Management
TM
Nasolution is the first smart nasal solution for the safe self-administration of intranasal medication at home
Providing Compliance Solutions
With non-adherence of medications costing the U.S. $300 billion annually, the FDA and pharmaceutical industry are calling for devices that curb abuse and improve patient compliance.
​
Nasolution is the answer to this call, providing both doctors and patients peace of mind. The world is shifting towards customized at-home telemedicine and it’s time the intranasal industry joins in.
How It Works
Our advanced patent pending technology ensures safe and compliant drug delivery through its core features
Controlled Dosing
Sealed bottle, filled by pharmacist, will only release exact dose at specified times
Tamper Resistance
Patients unable to access medication dose before scheduled times
Physician Oversight
Delivers alerts to doctors for oversight and patient adherence
Cloud Connectivity
Sends reminders to patients and monitors, collects and forwards data to physicians
Applications
Because of its dosage control, remote regulation, and monitoring, Nasolution is the perfect system for intranasal drug delivery treatments with:
Danger of Abuse
Nasolution increases safety and keeps patients accountable
Narrow Therapeutic Window
Nasolution maintains precision and only releases the exact amount of drug prescribed to patients
Poor Compliance
Nasolution sends reminders to patients, especially helpful in elderly and long-term care facilities
Who We Are
Cross-functional team of Georgia Tech engineers
%20(1).png)
Brandon Kleber
CEO
B.S. Mechanical Engineering, Georgia Tech
%20(1).png)
Jacob Banov
COO
B.S. Biomedical Engineering, Georgia Tech
%2520(1)_edited_pn.png)
Adam Verga
CTO
B.S. Materials Engineering, Georgia Tech
%20(1).png)
Isaac Abadi
CDO
B.S. Computer Engineering, Georgia Tech
Advisory Board
Yancy Riddle, PhD, PLD
NearShore Tech, COO
Armada Cloud, CEO
Ward Broom, MBA
Cathaid Inc., CEO
Intent Solutions, COO
Tom Baird, MSSM
Lobe Sciences, CEO
Mojave Jane Brands, COO
John Krystal, MD
Yale-New Haven Hospital, Chief of Psychiatry
We've Come a Long Way
We have been working for two years now to solve this problem that arose while investigating clinical trials for ketamine, a quickly growing antidepressant. The protocol for this intranasal administration requires patients to seek treatment in their doctor's office multiple times per week. Upon investigation, it was discovered that there is no method for patients or healthcare providers to track or monitor the administration of a given intranasal prescription. For ketamine, Nasolution aims to open a new market for patients that are unable to come in for regular treatments, thus offering them safe access to this life-saving medication that they otherwise wouldn't be able to take.
​
​
However, further research discovered that we were just scratching the surface of this technology's applications. There are a multitude of medications administered intranasally for which similar oversight and compliance technology could seriously improve the treatment process. Opiates, sleep disorder medications, Alzheimer's, Parkinson's medications... the list of treatments that this technology will unlock to not only be delivered, but be delivered safer, goes on and on.
Be in Touch
We look forward to hearing from you!